Literature DB >> 7946940

The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients.

R A Yeates1, M Ruhnke, G Pfaff, A Hartmann, M Trautmann, E Sarnow.   

Abstract

The pharmacokinetics of fluconazole after a single 100 mg i.v. dose were studied in 10 healthy subjects (5 M; 5 F) and 10 HIV-positive patients (8 M; 2 F). The mean value of plasma clearance was 25% lower in the patient groups (17 +/- 6 (s.d.) vs 23 +/- 4 ml min-1; 95% CI of difference -11 to -0.7; P < 0.05). This difference may have been related to slightly reduced kidney function in the patient group (mean creatinine clearance -18%) but is unlikely to be clinically significant. Therefore, no adjustment of the dose of intravenously administered fluconazole appears to be necessary in AIDS patients without clinical signs of enteropathy.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7946940      PMCID： PMC1364841          DOI： 10.1111/j.1365-2125.1994.tb04325.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Renal failure in patients with AIDS-related complex.

Authors:  N H Coleburn; J V Scholes; F C Lowe
Journal:  Urology       Date:  1991-06       Impact factor: 2.649

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

Review 3.  Azoles and AIDS.

Authors:  R A Larsen
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

Review 4.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

5.  Drug interactions with fluconazole.

Authors:  J D Lazar; K D Wilner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

6.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.

Authors:  W G Powderly; M S Saag; G A Cloud; P Robinson; R D Meyer; J M Jacobson; J R Graybill; A M Sugar; V J McAuliffe; S E Follansbee
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

Review 7.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

8.  Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients.

Authors:  B Dupont; E Drouhet
Journal:  J Med Vet Mycol       Date:  1988-02

9.  Fluconazole penetration into cerebrospinal fluid in humans.

Authors:  G Foulds; D R Brennan; C Wajszczuk; A Catanzaro; D C Garg; W Knopf; M Rinaldi; D J Weidler
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126
  9 in total
  11 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients.

Authors:  A El-Yazigi; M Ellis; P Ernst; D Spence; R Hussain; F J Baillie
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindolol.

Authors:  A S Gross; A J McLachlan; I Minns; J B Beal; S E Tett
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 4.  Role of viral infections in the induction of adverse drug reactions.

Authors:  M Levy
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.228

5.  Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.

Authors:  Juliana F Roos; Carl M J Kirkpatrick; Susan E Tett; Andrew J McLachlan; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

Review 6.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

7.  Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.

Authors:  Karen Marie Thyssen Astvad; Joseph Meletiadis; Sarah Whalley; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

8.  Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection.

Authors:  S Tett; S Moore; J Ray
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

9.  First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.

Authors:  Wei Zhao; Chantal Le Guellec; Daniel K Benjamin; William W Hope; Thomas Bourgeois; Kevin M Watt; Johannes N van den Anker; Boris Matrot; Harri Saxen; Kalle Hoppu; Paolo Manzoni; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

10.  Developmental changes of fluconazole clearance in neonates and infants in relation to ontogeny of glomerular filtration rate: literature review and data analysis.

Authors:  Kazutoshi Murakoso; Ryoichi Minagawa; Hirotoshi Echizen
Journal:  J Pharm Health Care Sci       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.